Project Grant R15HL186347
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $561K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ottawa Hills, OH 43606, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Pennsylvania $635,421 in Project Grant R01HL179069 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into how the transcription factor RUNX1 restrains inflammatory signaling in granulocyte-monocyte progenitors and neutrophils. The research addresses familial platelet disorder...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $715,504 for Project Grant R01HL187582 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will investigate the regulation of long-lasting hematopoietic multipotent progenitors (MPPs) and the mechanisms by which immune signals shape their functional properties. The research addresses evolving understanding of hematopoietic cell production dynamics,...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $218,728 in project grant funding on March 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds spatial immunophenotyping of tuberculosis granulomas, with work performed at OHSU's Portland, Oregon campus through September 16, 2029. The project applies an extensive panel of Mycobacterium tuberculosis antigen-specific probes—including commercial antibodies, novel...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the Department of Health and Human Services National Institutes of Health, awarded $753,539 to the University of Cincinnati Sponsored Research Services Division on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of CPNE5 (Copine 5) in cardiovascular barrier dysfunction and septic cardiomyopathy. The research addresses sepsis-induced heart failure through mechanistic study...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart Lung and Blood Institute awarded Sloan-Kettering Institute For Cancer Research $169,020 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research on the role of ZBTB1 in normal and clonal hematopoiesis. The award funds a career development project investigating how epigenetic dysregulation of ZBTB1 drives clonal advantage in DNMT3A-mutant hematopoietic stem cells and contributes to clonal hematopoiesis, a premalignant condition...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $292,500 Project Grant to Sanford Burnham Prebys Medical Discovery Institute effective August 15, 2025, through July 31, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837). This interdisciplinary research project aims to identify and characterize novel microproteins encoded by small open reading frames (SMORFs) that play critical roles in normal hematopoiesis and hematopoietic...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $776,511 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. This award supports research to develop and validate a three-dimensional engineered hemogenic vascular niche model designed to elucidate the microenvironmental factors that promote hematopoietic stem...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the regulation of ribosomal RNA transcription by MYC in hematopoiesis. The funded research dissects how MYC, a developmental transcription factor often dysregulated in disease, directly regulates ribosomal RNA (rRNA) transcription by RNA polymerase I in hematopoietic cells. The work addresses a...